Immunovant, Inc. SEC Filings

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin report their beneficial ownership of Immunovant, Inc. common stock on an amended Schedule 13G. As of June 30, 2026, they collectively beneficially owned 9,341,151 shares of common stock, representing 4.55% of the class.

The filing states that all 9,341,151 shares are subject to shared voting and shared dispositive power, with no sole voting or dispositive power reported for any of the filers. The percentage ownership is calculated using 205,308,917 Immunovant common shares outstanding as of May 14, 2026, as disclosed in Immunovant’s Form 10-K. The report is filed jointly, and Deep Track Capital, LP is identified as the relevant entity for which David Kroin may be considered a control person.

Immunovant, Inc., a clinical-stage immunology company focused on anti-FcRn antibody IMVT-1402, reported a net loss of $153.2 million for the quarter ended June 30, 2026, compared with $120.6 million a year earlier. Research and development expenses rose by $41.4 million to $142.6 million, driven by expanded IMVT-1402 programs in endocrine, neurological, rheumatology and dermatology diseases, while general and administrative expenses declined by $8.3 million to $17.7 million.

Cash and cash equivalents were $797.8 million, with operating activities using $124.4 million in cash in the quarter. Based on its current operating plan, the company expects this cash to fund operating expenses and capital expenditures to the potential commercial launch of IMVT-1402 in Graves’ disease, though it acknowledges a need to raise additional capital to fully implement its broader business plan.

The development pipeline centers on IMVT-1402 in six autoimmune indications, including potentially registrational trials in Graves’ disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, CIDP and Sjögren’s disease, plus a proof-of-concept study in cutaneous lupus erythematosus. In a difficult-to-treat rheumatoid arthritis trial, open-label Period 1 Week 16 results showed ACR20/50/70 response rates of 72.7%/54.5%/35.8% in a heavily pretreated population, with no new drug-related safety signals observed, and further data are expected in the second half of calendar 2026.

Immunovant, Inc. reported corporate updates and financial results for its fiscal first quarter ended June 30, 2026, centered on the development of IMVT-1402 across six autoimmune indications, including Graves’ disease, myasthenia gravis, CIDP, difficult-to-treat rheumatoid arthritis, Sjögren’s disease and cutaneous lupus erythematosus.

As of June 30, 2026, cash and cash equivalents were $797.8 million, which the company states provides runway to the potential commercial launch of IMVT-1402 in Graves’ disease based on its current operating plan. For the quarter, R&D expenses were $142.6 million, up from $101.2 million a year earlier, mainly from IMVT-1402 clinical and manufacturing activities, while G&A expenses declined to $17.7 million from $26.0 million. Net loss was $153.2 million, or $0.75 per share, versus $120.6 million, or $0.71 per share, in the prior-year quarter. Non-GAAP measures exclude $13.8 million of non-cash stock-based compensation. The company highlighted upcoming IMVT-1402 milestones, including D2T RA and CLE data in the second half of 2026, GD and MG topline data in 2027, and CIDP and Sjögren’s data in 2028.

Immunovant director Atul Pande exercised stock options for 1,500 shares of Common Stock at $8.43 per share and on the same date sold 1,500 shares at $39.80 per share. The option exercise involved a fully vested award and left 66,681 option shares outstanding. In addition, 20,000 Common Shares are held indirectly by a trust. All reported trades occurred under a Rule 10b5-1 trading plan adopted on December 26, 2025.

Immunovant, Inc. Chief Financial Officer Tiago Girao reported the sale of 6,798 shares of common stock on July 23, 2026 at a weighted average price of $38.69 per share. The mandated “sell to cover” transaction funded tax withholding on 13,024 vested RSUs, leaving him with 240,798 shares held directly.

Immunovant, Inc. reports that Chief Technology Officer Jay S. Stout sold 2,857 shares of common stock on July 23, 2026 at a weighted average price of $38.69 per share, with sale prices ranging from $38.18 to $39.05. The shares were sold to cover tax withholding obligations from the July 17, 2026 vesting of 6,250 restricted stock units from a 100,000-unit grant. After this mandated sell-to-cover transaction, he directly holds 205,341 shares of Immunovant common stock.

Immunovant, Inc. will hold its 2026 annual stockholders meeting virtually on September 2, 2026 at 1:00 p.m. Eastern Time. Holders of common stock and Series A preferred stock as of July 8, 2026 may vote on three items: electing directors Jacob Bauer, Douglas Hughes and Robert Susman; ratifying Ernst & Young LLP as independent auditor for the year ending March 31, 2027; and a non-binding advisory vote approving named executive officer compensation.

On the record date there were 206,402,338 common shares and 10,000 Series A preferred shares entitled to vote; Roivant Sciences Ltd. beneficially owned 54.9% of common stock and elects four of seven directors, making Immunovant a Nasdaq “controlled company” that uses certain governance exemptions while maintaining a fully independent three‑member Audit Committee. The proxy describes board structure, committee responsibilities, ownership detail, and a pay‑for‑performance executive compensation program using cash bonuses, options, RSUs, PSUs and CEO capped value appreciation rights.

Immunovant, Inc. Chief Operating Officer Gloria Melanie reported two open-market sales totaling 2,036 shares of common stock on July 8, 2026. According to the disclosure, these shares were sold solely to cover tax withholding obligations arising from the July 1, 2026 vesting and settlement of previously granted restricted stock units, under a mandated “sell to cover” arrangement rather than a discretionary trade.